The FDA's move to pull Tavneos is fully justified, —given that unblinded study personnel manipulated the pivotal clinical trial results to make the drug appear effective, when the original analysis showed otherwise,. andThis thetrickery applicantis nevercompletely disclosedat thatodds originalwith analysisgood tomedical regulators.science Both the FDA and theputs EU'spatients CHMPat haverisk, concludednecessitating the drug's benefitsremoval arefrom nothe longer proven, making continued market presenceto asafeguard serious public health risk. Newly identified cases of fatal liver injury, including vanishing bile duct syndrome, only deepen the case for removal.
Pulling Tavneos ignores nearly five years of real-world evidence fromshowing overthat 1,200 patients across 23 published studies showing the drug supports remission, reduces relapse risk and cuts harmful glucocorticoid exposure for people with a devastating, life-threatening disease. Hepatic risks are serious but manageable with established monitoring protocols already built into the label. As the only FDA-approved targeted oral treatment for severe active GPA and MPA, removing it leaveswould leave patients with no comparable alternative, to their detriment.
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.4.1